JP2007529558A5 - - Google Patents

Info

Publication number

JP2007529558A5

JP2007529558A5 JP2007504170A JP2007504170A JP2007529558A5 JP 2007529558 A5 JP2007529558 A5 JP 2007529558A5 JP 2007504170 A JP2007504170 A JP 2007504170A JP 2007504170 A JP2007504170 A JP 2007504170A JP 2007529558 A5 JP2007529558 A5 JP 2007529558A5

Authority

JP

Japan

Prior art keywords

hiv

cells

cell

liposomes

targeting

Prior art date

2005-03-21

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000002502 liposome Substances 0.000 claims description 251
• 239000003795 chemical substances by application Substances 0.000 claims description 154
• 230000027455 binding Effects 0.000 claims description 87
• 230000001717 pathogenic Effects 0.000 claims description 79
• 244000052769 pathogens Species 0.000 claims description 72
• 150000002632 lipids Chemical class 0.000 claims description 59
• PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 44
• SHZGCJCMOBCMKK-DHVFOXMCSA-N Fucose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 41
• 239000003446 ligand Substances 0.000 claims description 28
• 239000003726 plant lectin Substances 0.000 claims description 27
• 229910001428 transition metal ion Inorganic materials 0.000 claims description 3
• 150000001768 cations Chemical class 0.000 claims description 2
• 239000005515 coenzyme Substances 0.000 claims description 2
• 101700036312 CONA Proteins 0.000 claims 1
• 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 1
• 239000003248 enzyme activator Substances 0.000 claims 1
• 210000004027 cells Anatomy 0.000 description 337
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 238
• 210000004443 Dendritic Cells Anatomy 0.000 description 170
• 241000282414 Homo sapiens Species 0.000 description 113
• 102000005962 receptors Human genes 0.000 description 103
• 108020003175 receptors Proteins 0.000 description 103
• 239000002523 lectin Substances 0.000 description 101
• 210000001744 T-Lymphocytes Anatomy 0.000 description 86
• 210000002540 Macrophages Anatomy 0.000 description 85
• 241000700605 Viruses Species 0.000 description 78
• 210000001616 Monocytes Anatomy 0.000 description 76
• 230000002458 infectious Effects 0.000 description 72
• 101710043079 ADAM11 Proteins 0.000 description 70
• 201000009910 diseases by infectious agent Diseases 0.000 description 70
• 210000000182 CD11c+CD123- DC Anatomy 0.000 description 65
• 208000005721 HIV Infections Diseases 0.000 description 65
• 239000003814 drug Substances 0.000 description 64
• 230000003834 intracellular Effects 0.000 description 61
• 229940079593 drugs Drugs 0.000 description 55
• 150000001875 compounds Chemical class 0.000 description 49
• 102000003930 C-Type Lectins Human genes 0.000 description 43
• 108090000342 C-Type Lectins Proteins 0.000 description 43
• 102000004169 proteins and genes Human genes 0.000 description 41
• 108090000623 proteins and genes Proteins 0.000 description 41
• 235000018102 proteins Nutrition 0.000 description 40
• 239000000203 mixture Substances 0.000 description 39
• 102000004856 Lectins Human genes 0.000 description 38
• 108090001090 Lectins Proteins 0.000 description 38
• 210000001185 Bone Marrow Anatomy 0.000 description 36
• 150000001720 carbohydrates Chemical class 0.000 description 36
• 239000012528 membrane Substances 0.000 description 35
• 235000000346 sugar Nutrition 0.000 description 35
• 238000000338 in vitro Methods 0.000 description 34
• 210000001519 tissues Anatomy 0.000 description 34
• 101710034340 Os04g0173800 Proteins 0.000 description 33
• 235000014633 carbohydrates Nutrition 0.000 description 33
• 230000001225 therapeutic Effects 0.000 description 33
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 32
• 101710015954 HVA1 Proteins 0.000 description 32
• 101700065814 LEA2 Proteins 0.000 description 32
• 101700021338 LEC Proteins 0.000 description 32
• 101700077545 LECC Proteins 0.000 description 32
• 101700028499 LECG Proteins 0.000 description 32
• 101700063913 LECT Proteins 0.000 description 32
• 101700036391 lecA Proteins 0.000 description 32
• 101700001016 mbhA Proteins 0.000 description 32
• 210000004379 Membranes Anatomy 0.000 description 31
• 102000038129 antigens Human genes 0.000 description 31
• 230000004069 differentiation Effects 0.000 description 31
• 239000000427 antigen Substances 0.000 description 30
• 108091007172 antigens Proteins 0.000 description 30
• 210000000056 organs Anatomy 0.000 description 30
• HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 29
• 230000000694 effects Effects 0.000 description 29
• 108010062580 Concanavalin A Proteins 0.000 description 28
• 229920003013 deoxyribonucleic acid Polymers 0.000 description 27
• 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 26
• 230000015572 biosynthetic process Effects 0.000 description 25
• 230000002401 inhibitory effect Effects 0.000 description 25
• 238000000034 method Methods 0.000 description 25
• 210000001163 Endosomes Anatomy 0.000 description 24
• 108010031099 mannose receptor Proteins 0.000 description 24
• 230000001404 mediated Effects 0.000 description 24
• 210000004369 Blood Anatomy 0.000 description 23
• DEGAKNSWVGKMLS-UHFFFAOYSA-N Calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 23
• 229960002378 Oftasceine Drugs 0.000 description 23
• 230000005540 biological transmission Effects 0.000 description 23
• 239000008280 blood Substances 0.000 description 23
• 230000001684 chronic Effects 0.000 description 23
• 241000711549 Hepacivirus C Species 0.000 description 22
• 101710023234 Segment 5 Proteins 0.000 description 22
• 210000001165 Lymph Nodes Anatomy 0.000 description 21
• 108010047245 Myrianthus holstii lectin Proteins 0.000 description 21
• 230000001965 increased Effects 0.000 description 21
• 201000010099 disease Diseases 0.000 description 20
• 230000003993 interaction Effects 0.000 description 20
• 210000004185 Liver Anatomy 0.000 description 19
• 201000011510 cancer Diseases 0.000 description 19
• 201000001820 human immunodeficiency virus infectious disease Diseases 0.000 description 19
• -1 DC-SIGN Proteins 0.000 description 18
• 239000011886 peripheral blood Substances 0.000 description 18
• 210000000285 Dendritic Cells, Follicular Anatomy 0.000 description 17
• 230000001413 cellular Effects 0.000 description 17
• 230000001419 dependent Effects 0.000 description 17
• 230000036039 immunity Effects 0.000 description 16
• 239000000243 solution Substances 0.000 description 16
• 238000003786 synthesis reaction Methods 0.000 description 16
• 108020003282 C-type lectin receptors Proteins 0.000 description 15
• 102000035392 C-type lectin receptors Human genes 0.000 description 15
• 229940107161 Cholesterol Drugs 0.000 description 15
• 210000000865 Mononuclear Phagocyte System Anatomy 0.000 description 15
• XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
• 235000012000 cholesterol Nutrition 0.000 description 15
• 230000018109 developmental process Effects 0.000 description 15
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
• 238000003860 storage Methods 0.000 description 15
• 230000002194 synthesizing Effects 0.000 description 15
• 102000004190 Enzymes Human genes 0.000 description 14
• 108090000790 Enzymes Proteins 0.000 description 14
• 108010089814 Plant Lectins Proteins 0.000 description 14
• 210000002845 Virion Anatomy 0.000 description 14
• 238000011161 development Methods 0.000 description 14
• ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 14
• 239000007924 injection Substances 0.000 description 14
• 229920001542 oligosaccharide Polymers 0.000 description 14
• 150000002482 oligosaccharides Polymers 0.000 description 14
• 239000000047 product Substances 0.000 description 14
• 230000004044 response Effects 0.000 description 14
• 102000002086 C-type lectin-like Human genes 0.000 description 13
• 108050009406 C-type lectin-like Proteins 0.000 description 13
• 102100012080 CCR5 Human genes 0.000 description 13
• 101700043583 CCR5 Proteins 0.000 description 13
• 102100006400 CSF2 Human genes 0.000 description 13
• 101700082799 IL2RA Proteins 0.000 description 13
• 101700015336 ISG20 Proteins 0.000 description 13
• 102100002950 ISG20 Human genes 0.000 description 13
• 210000003563 Lymphoid Tissue Anatomy 0.000 description 13
• 108090001123 antibodies Proteins 0.000 description 13
• 102000004965 antibodies Human genes 0.000 description 13
• 239000003112 inhibitor Substances 0.000 description 13
• 238000002560 therapeutic procedure Methods 0.000 description 13
• 210000004556 Brain Anatomy 0.000 description 12
• 210000002966 Serum Anatomy 0.000 description 12
• 230000001566 pro-viral Effects 0.000 description 12
• 210000000612 Antigen-Presenting Cells Anatomy 0.000 description 11
• 206010059512 Apoptosis Diseases 0.000 description 11
• 210000001035 Gastrointestinal Tract Anatomy 0.000 description 11
• 102000004388 Interleukin-4 Human genes 0.000 description 11
• 108090000978 Interleukin-4 Proteins 0.000 description 11
• 108010087870 Mannose-Binding Lectin Proteins 0.000 description 11
• 102000009112 Mannose-Binding Lectin Human genes 0.000 description 11
• 206010053219 Non-alcoholic steatohepatitis Diseases 0.000 description 11
• 101700002305 Reg1 Proteins 0.000 description 11
• 230000001464 adherent Effects 0.000 description 11
• 230000006907 apoptotic process Effects 0.000 description 11
• 238000010192 crystallographic characterization Methods 0.000 description 11
• 230000002708 enhancing Effects 0.000 description 11
• 238000000684 flow cytometry Methods 0.000 description 11
• 238000002347 injection Methods 0.000 description 11
• OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 11
• 238000010186 staining Methods 0.000 description 11
• 239000000700 tracer Substances 0.000 description 11
• 230000003612 virological Effects 0.000 description 11
• 102100013082 CD1A Human genes 0.000 description 10
• 101700015984 CD1A Proteins 0.000 description 10
• 230000037250 Clearance Effects 0.000 description 10
• 229940088598 Enzyme Drugs 0.000 description 10
• 210000003494 Hepatocytes Anatomy 0.000 description 10
• 101700018962 KLRG1 Proteins 0.000 description 10
• 102100019596 KLRG1 Human genes 0.000 description 10
• 241000187479 Mycobacterium tuberculosis Species 0.000 description 10
• 229940010383 Mycobacterium tuberculosis Drugs 0.000 description 10
• 208000008338 Non-alcoholic Fatty Liver Disease Diseases 0.000 description 10
• 108009000135 Nonalcoholic fatty liver disease Proteins 0.000 description 10
• 230000002776 aggregation Effects 0.000 description 10
• 238000004220 aggregation Methods 0.000 description 10
• HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
• 230000035512 clearance Effects 0.000 description 10
• 230000001086 cytosolic Effects 0.000 description 10
• 238000004519 manufacturing process Methods 0.000 description 10
• OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
• 230000002093 peripheral Effects 0.000 description 10
• 239000012071 phase Substances 0.000 description 10
• 102100007788 APC Human genes 0.000 description 9
• GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 9
• 102000003886 Glycoproteins Human genes 0.000 description 9
• 108090000288 Glycoproteins Proteins 0.000 description 9
• 241000282412 Homo Species 0.000 description 9
• 210000000822 Killer Cells, Natural Anatomy 0.000 description 9
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 9
• 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 9
• 230000015556 catabolic process Effects 0.000 description 9
• 239000000975 dye Substances 0.000 description 9
• 230000002132 lysosomal Effects 0.000 description 9
• 230000001575 pathological Effects 0.000 description 9
• 150000003904 phospholipids Chemical class 0.000 description 9
• 239000004417 polycarbonate Substances 0.000 description 9
• 229920001223 polyethylene glycol Polymers 0.000 description 9
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
• 239000000126 substance Substances 0.000 description 9
• 150000008163 sugars Chemical class 0.000 description 9
• 230000001629 suppression Effects 0.000 description 9
• 239000000725 suspension Substances 0.000 description 9
• 241000894006 Bacteria Species 0.000 description 8
• 102100004346 CLEC4C Human genes 0.000 description 8
• 101710026582 CLEC4C Proteins 0.000 description 8
• 239000002202 Polyethylene glycol Substances 0.000 description 8
• 102000014961 Protein Precursors Human genes 0.000 description 8
• 108010078762 Protein Precursors Proteins 0.000 description 8
• SNKAWJBJQDLSFF-YEUCEMRASA-N [2-({2,3-bis[(9Z)-octadec-9-enoyloxy]propyl phosphonato}oxy)ethyl]trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-YEUCEMRASA-N 0.000 description 8
• 230000004087 circulation Effects 0.000 description 8
• 230000004059 degradation Effects 0.000 description 8
• 238000006731 degradation reaction Methods 0.000 description 8
• RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
• 238000001704 evaporation Methods 0.000 description 8
• 238000005755 formation reaction Methods 0.000 description 8
• 238000002955 isolation Methods 0.000 description 8
• 230000001264 neutralization Effects 0.000 description 8
• 230000037361 pathway Effects 0.000 description 8
• 230000001105 regulatory Effects 0.000 description 8
• 230000037177 Biodistribution Effects 0.000 description 7
• 210000002987 Choroid Plexus Anatomy 0.000 description 7
• 241000701022 Cytomegalovirus Species 0.000 description 7
• 210000001821 Langerhans Cells Anatomy 0.000 description 7
• 241001626183 Myrianthus Species 0.000 description 7
• 229940067631 Phospholipids Drugs 0.000 description 7
• 102100006059 REG1A Human genes 0.000 description 7
• 101700052509 REG1A Proteins 0.000 description 7
• 208000001756 Virus Disease Diseases 0.000 description 7
• 239000002253 acid Substances 0.000 description 7
• 230000004913 activation Effects 0.000 description 7
• 239000011575 calcium Substances 0.000 description 7
• KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
• 230000001900 immune effect Effects 0.000 description 7
• 239000003550 marker Substances 0.000 description 7
• 230000003169 placental Effects 0.000 description 7
• 238000002360 preparation method Methods 0.000 description 7
• 230000002829 reduced Effects 0.000 description 7
• 210000003289 regulatory T cell Anatomy 0.000 description 7
• 241000894007 species Species 0.000 description 7
• 238000003756 stirring Methods 0.000 description 7
• 238000007920 subcutaneous administration Methods 0.000 description 7
• WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 7
• ZAKBPRIDLSBYQQ-VHSXEESVSA-N 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OC[C@@H](O)CO ZAKBPRIDLSBYQQ-VHSXEESVSA-N 0.000 description 6
• 102100003268 CD14 Human genes 0.000 description 6
• 101700027514 CD14 Proteins 0.000 description 6
• 101700013105 CD83 Proteins 0.000 description 6
• 102100008186 CD83 Human genes 0.000 description 6
• 210000002889 Endothelial Cells Anatomy 0.000 description 6
• 210000002767 Hepatic Artery Anatomy 0.000 description 6
• SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 6
• 101700062805 LY75 Proteins 0.000 description 6
• 102100011002 LY75 Human genes 0.000 description 6
• 102100004732 MRC1 Human genes 0.000 description 6
• 210000004251 Milk, Human Anatomy 0.000 description 6
• OVRNDRQMDRJTHS-FMDGEEDCSA-N N-Acetylglucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 6
• 210000002381 Plasma Anatomy 0.000 description 6
• CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
• 238000007792 addition Methods 0.000 description 6
• 238000004458 analytical method Methods 0.000 description 6
• 230000000840 anti-viral Effects 0.000 description 6
• 239000002246 antineoplastic agent Substances 0.000 description 6
• 230000001640 apoptogenic Effects 0.000 description 6
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
• 230000012010 growth Effects 0.000 description 6
• 235000020256 human milk Nutrition 0.000 description 6
• 230000036571 hydration Effects 0.000 description 6
• 238000006703 hydration reaction Methods 0.000 description 6
• 230000015654 memory Effects 0.000 description 6
• 229910052751 metal Inorganic materials 0.000 description 6
• 239000002184 metal Substances 0.000 description 6
• 230000004048 modification Effects 0.000 description 6
• 238000006011 modification reaction Methods 0.000 description 6
• 239000003960 organic solvent Substances 0.000 description 6
• 230000002085 persistent Effects 0.000 description 6
• 230000035935 pregnancy Effects 0.000 description 6
• 239000011541 reaction mixture Substances 0.000 description 6
• 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 6
• 238000001228 spectrum Methods 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• 210000003719 B-Lymphocytes Anatomy 0.000 description 5
• 101710026584 CD207 Proteins 0.000 description 5
• 102100010225 CD207 Human genes 0.000 description 5
• 206010009944 Colon cancer Diseases 0.000 description 5
• 210000000805 Cytoplasm Anatomy 0.000 description 5
• 241000196324 Embryophyta Species 0.000 description 5
• 210000003743 Erythrocytes Anatomy 0.000 description 5
• 210000004700 Fetal Blood Anatomy 0.000 description 5
• 206010016654 Fibrosis Diseases 0.000 description 5
• 102000006354 HLA-DR Antigens Human genes 0.000 description 5
• 108010058597 HLA-DR Antigens Proteins 0.000 description 5
• 208000006454 Hepatitis Diseases 0.000 description 5
• 241000725303 Human immunodeficiency virus Species 0.000 description 5
• 206010061218 Inflammation Diseases 0.000 description 5
• 210000000265 Leukocytes Anatomy 0.000 description 5
• 210000004698 Lymphocytes Anatomy 0.000 description 5
• 210000003712 Lysosomes Anatomy 0.000 description 5
• 241001465754 Metazoa Species 0.000 description 5
• 206010028980 Neoplasm Diseases 0.000 description 5
• 210000004940 Nucleus Anatomy 0.000 description 5
• 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 5
• UNJJBGNPUUVVFQ-ZJUUUORDSA-N Phosphatidylserine Chemical compound CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O UNJJBGNPUUVVFQ-ZJUUUORDSA-N 0.000 description 5
• 206010038038 Rectal cancer Diseases 0.000 description 5
• FIAFUQMPZJWCLV-UHFFFAOYSA-N Suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 5
• 229960005314 Suramin Drugs 0.000 description 5
• 230000000798 anti-retroviral Effects 0.000 description 5
• 238000001125 extrusion Methods 0.000 description 5
• 230000004761 fibrosis Effects 0.000 description 5
• 230000004927 fusion Effects 0.000 description 5
• 231100000283 hepatitis Toxicity 0.000 description 5
• 238000000265 homogenisation Methods 0.000 description 5
• 210000002865 immune cell Anatomy 0.000 description 5
• 230000028993 immune response Effects 0.000 description 5
• 230000004054 inflammatory process Effects 0.000 description 5
• 238000011068 load Methods 0.000 description 5
• 230000001868 lysosomic Effects 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 210000004877 mucosa Anatomy 0.000 description 5
• 230000008506 pathogenesis Effects 0.000 description 5
• 230000002688 persistence Effects 0.000 description 5
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 5
• 229920000515 polycarbonate Polymers 0.000 description 5
• 230000003389 potentiating Effects 0.000 description 5
• 230000001681 protective Effects 0.000 description 5
• 201000001275 rectum cancer Diseases 0.000 description 5
• 230000028327 secretion Effects 0.000 description 5
• 238000000926 separation method Methods 0.000 description 5
• 201000008827 tuberculosis Diseases 0.000 description 5
• 239000003981 vehicle Substances 0.000 description 5
• 229920000160 (ribonucleotides)n+m Polymers 0.000 description 4
• 210000001130 Astrocytes Anatomy 0.000 description 4
• 206010003816 Autoimmune disease Diseases 0.000 description 4
• APKFDSVGJQXUKY-INPOYWNPSA-N BRL-49594 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 4
• 102100002212 CXCR4 Human genes 0.000 description 4
• 101710003734 CXCR4 Proteins 0.000 description 4
• 210000000170 Cell Membrane Anatomy 0.000 description 4
• 210000003169 Central Nervous System Anatomy 0.000 description 4
• 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 4
• 102000004405 Collectins Human genes 0.000 description 4
• 108090000909 Collectins Proteins 0.000 description 4
• 235000004418 Durio kutejensis Nutrition 0.000 description 4
• 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 4
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 4
• 239000007995 HEPES buffer Substances 0.000 description 4
• 208000005176 Hepatitis C Diseases 0.000 description 4
• 210000000987 Immune System Anatomy 0.000 description 4
• 210000004347 Intestinal Mucosa Anatomy 0.000 description 4
• 210000002433 Leukocytes, Mononuclear Anatomy 0.000 description 4
• OYHQOLUKZRVURQ-IXWMQOLASA-N Linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 4
• 101700029479 MRC1 Proteins 0.000 description 4
• 210000000274 Microglia Anatomy 0.000 description 4
• 210000004400 Mucous Membrane Anatomy 0.000 description 4
• 229950006780 N-Acetylglucosamine Drugs 0.000 description 4
• 210000002826 Placenta Anatomy 0.000 description 4
• 206010047461 Viral infection Diseases 0.000 description 4
• 238000009825 accumulation Methods 0.000 description 4
• 230000000890 antigenic Effects 0.000 description 4
• 235000013405 beer Nutrition 0.000 description 4
• 210000002798 bone marrow cell Anatomy 0.000 description 4
• 210000003008 brain-resident macrophage Anatomy 0.000 description 4
• UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• 238000000502 dialysis Methods 0.000 description 4
• 238000009826 distribution Methods 0.000 description 4
• 230000012202 endocytosis Effects 0.000 description 4
• 238000005516 engineering process Methods 0.000 description 4
• 239000012091 fetal bovine serum Substances 0.000 description 4
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
• 239000000727 fraction Substances 0.000 description 4
• 230000002496 gastric Effects 0.000 description 4
• 210000002443 helper T lymphocyte Anatomy 0.000 description 4
• 229940020899 hematological Enzymes Drugs 0.000 description 4
• 230000002440 hepatic Effects 0.000 description 4
• 230000001939 inductive effect Effects 0.000 description 4
• 238000001802 infusion Methods 0.000 description 4
• 239000000543 intermediate Substances 0.000 description 4
• 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 4
• 230000002025 microglial Effects 0.000 description 4
• 230000000051 modifying Effects 0.000 description 4
• 230000004660 morphological change Effects 0.000 description 4
• 230000003287 optical Effects 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 230000003362 replicative Effects 0.000 description 4
• 231100000486 side effect Toxicity 0.000 description 4
• 230000011664 signaling Effects 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• 239000007787 solid Substances 0.000 description 4
• 210000000130 stem cell Anatomy 0.000 description 4
• 150000003431 steroids Chemical class 0.000 description 4
• 230000000638 stimulation Effects 0.000 description 4
• 239000006228 supernatant Substances 0.000 description 4
• 201000010874 syndrome Diseases 0.000 description 4
• 238000007910 systemic administration Methods 0.000 description 4
• YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
• 230000002588 toxic Effects 0.000 description 4
• 231100000331 toxic Toxicity 0.000 description 4
• 230000035897 transcription Effects 0.000 description 4
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
• 241001430294 unidentified retrovirus Species 0.000 description 4
• 230000017613 viral reproduction Effects 0.000 description 4
• PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 3
• COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
• NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 3
• GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
• AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 3
• 101710027066 ALB Proteins 0.000 description 3
• 229960001230 Asparagine Drugs 0.000 description 3
• 101710040446 CD40 Proteins 0.000 description 3
• 102100013137 CD40 Human genes 0.000 description 3
• 101710026585 CLEC4M Proteins 0.000 description 3
• 102100010226 CLEC4M Human genes 0.000 description 3
• 102100018679 COLEC12 Human genes 0.000 description 3
• 101710030029 COLEC12 Proteins 0.000 description 3
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 3
• 102000007644 Colony-Stimulating Factors Human genes 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• 210000004544 DC2 Anatomy 0.000 description 3
• 210000001787 Dendrites Anatomy 0.000 description 3
• 101700057458 Drice Proteins 0.000 description 3
• 101710006782 EIF4G2 Proteins 0.000 description 3
• 102000033180 ERVK-6 Human genes 0.000 description 3
• 101710038044 ERVK-6 Proteins 0.000 description 3
• 101710027967 ERVW-1 Proteins 0.000 description 3
• 210000002615 Epidermis Anatomy 0.000 description 3
• 102100015541 FCGR3A Human genes 0.000 description 3
• 101710044656 FCGR3A Proteins 0.000 description 3
• 101710044657 FCGR3B Proteins 0.000 description 3
• 241000713800 Feline immunodeficiency virus Species 0.000 description 3
• 210000003754 Fetus Anatomy 0.000 description 3
• 108060003412 GRP Proteins 0.000 description 3
• 210000001280 Germinal Center Anatomy 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 102000015779 HDL Lipoproteins Human genes 0.000 description 3
• 230000036499 Half live Effects 0.000 description 3
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
• 102000004851 Immunoglobulin G Human genes 0.000 description 3
• 108010014726 Interferon Type I Proteins 0.000 description 3
• 102000002227 Interferon Type I Human genes 0.000 description 3
• 108010050904 Interferons Proteins 0.000 description 3
• 102000014150 Interferons Human genes 0.000 description 3
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
• 241000222722 Leishmania <genus> Species 0.000 description 3
• 210000004324 Lymphatic System Anatomy 0.000 description 3
• 241000282553 Macaca Species 0.000 description 3
• 101700030155 NAA15 Proteins 0.000 description 3
• 101700031697 NAT1 Proteins 0.000 description 3
• 238000005481 NMR spectroscopy Methods 0.000 description 3
• 210000002997 Osteoclasts Anatomy 0.000 description 3
• 101710042981 SHMT1 Proteins 0.000 description 3
• 101710016991 SLC38A6 Proteins 0.000 description 3
• 210000003491 Skin Anatomy 0.000 description 3
• 210000000225 Synapses Anatomy 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 238000006640 acetylation reaction Methods 0.000 description 3
• 125000000217 alkyl group Chemical group 0.000 description 3
• 150000001412 amines Chemical class 0.000 description 3
• 125000003277 amino group Chemical group 0.000 description 3
• 229960003942 amphotericin B Drugs 0.000 description 3
• 230000030741 antigen processing and presentation Effects 0.000 description 3
• 239000003443 antiviral agent Substances 0.000 description 3
• 108010006523 asialoglycoprotein receptor family Proteins 0.000 description 3
• 102000005427 asialoglycoprotein receptor family Human genes 0.000 description 3
• 235000009582 asparagine Nutrition 0.000 description 3
• 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 3
• 230000001580 bacterial Effects 0.000 description 3
• 102000024070 binding proteins Human genes 0.000 description 3
• 108091007650 binding proteins Proteins 0.000 description 3
• 231100000504 carcinogenesis Toxicity 0.000 description 3
• 125000002091 cationic group Chemical group 0.000 description 3
• 230000004700 cellular uptake Effects 0.000 description 3
• 230000002778 chronopharmacological Effects 0.000 description 3
• 230000000295 complement Effects 0.000 description 3
• 230000002596 correlated Effects 0.000 description 3
• 230000001472 cytotoxic Effects 0.000 description 3
• 231100000433 cytotoxic Toxicity 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 238000011026 diafiltration Methods 0.000 description 3
• 238000009792 diffusion process Methods 0.000 description 3
• 239000006185 dispersion Substances 0.000 description 3
• 238000003379 elimination reaction Methods 0.000 description 3
• 238000000799 fluorescence microscopy Methods 0.000 description 3
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
• 238000004108 freeze drying Methods 0.000 description 3
• 150000002270 gangliosides Chemical class 0.000 description 3
• 238000005227 gel permeation chromatography Methods 0.000 description 3
• 230000035784 germination Effects 0.000 description 3
• 230000028974 hepatocyte apoptotic process Effects 0.000 description 3
• 229910052739 hydrogen Inorganic materials 0.000 description 3
• 239000001257 hydrogen Substances 0.000 description 3
• CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
• 229920001477 hydrophilic polymer Polymers 0.000 description 3
• 230000002209 hydrophobic Effects 0.000 description 3
• 239000002955 immunomodulating agent Substances 0.000 description 3
• 230000002584 immunomodulator Effects 0.000 description 3
• 229940121354 immunomodulators Drugs 0.000 description 3
• 230000004957 immunoregulator effect Effects 0.000 description 3
• 238000009169 immunotherapy Methods 0.000 description 3
• 238000011065 in-situ storage Methods 0.000 description 3
• 230000002452 interceptive Effects 0.000 description 3
• 229940079322 interferon Drugs 0.000 description 3
• 230000000968 intestinal Effects 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 230000002147 killing Effects 0.000 description 3
• 239000010410 layer Substances 0.000 description 3
• 201000009673 liver disease Diseases 0.000 description 3
• 230000035800 maturation Effects 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• HOVAGTYPODGVJG-ZFYZTMLRSA-N methyl α-D-glucopyranoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-ZFYZTMLRSA-N 0.000 description 3
• CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
• 239000003226 mitogen Substances 0.000 description 3
• 238000002156 mixing Methods 0.000 description 3
• 108010045030 monoclonal antibodies Proteins 0.000 description 3
• 102000005614 monoclonal antibodies Human genes 0.000 description 3
• 239000000178 monomer Substances 0.000 description 3
• 150000002772 monosaccharides Chemical class 0.000 description 3
• 239000012044 organic layer Substances 0.000 description 3
• 230000002148 osteoclast Effects 0.000 description 3
• 230000000242 pagocytic Effects 0.000 description 3
• 244000045947 parasites Species 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• 230000036231 pharmacokinetics Effects 0.000 description 3
• 230000004977 physiological function Effects 0.000 description 3
• 230000035790 physiological processes and functions Effects 0.000 description 3
• 210000001778 pluripotent stem cell Anatomy 0.000 description 3
• 229920000499 poly(galactose) polymer Polymers 0.000 description 3
• 239000011148 porous material Substances 0.000 description 3
• 102000004196 processed proteins & peptides Human genes 0.000 description 3
• 108090000765 processed proteins & peptides Proteins 0.000 description 3
• 230000002035 prolonged Effects 0.000 description 3
• 238000011002 quantification Methods 0.000 description 3
• 238000003753 real-time PCR Methods 0.000 description 3
• 230000010837 receptor-mediated endocytosis Effects 0.000 description 3
• 238000004064 recycling Methods 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 230000000717 retained Effects 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 210000000352 storage cell Anatomy 0.000 description 3
• 238000010254 subcutaneous injection Methods 0.000 description 3
• 239000007929 subcutaneous injection Substances 0.000 description 3
• 102000002689 toll-like receptors Human genes 0.000 description 3
• 108020000411 toll-like receptors Proteins 0.000 description 3
• 238000002604 ultrasonography Methods 0.000 description 3
• ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 2
• WKJDWDLHIOUPPL-JSOSNVBQSA-N (2S)-2-amino-3-({[(2R)-2,3-bis(tetradecanoyloxy)propoxy](hydroxy)phosphoryl}oxy)propanoic acid Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCC WKJDWDLHIOUPPL-JSOSNVBQSA-N 0.000 description 2
• KLFKZIQAIPDJCW-HTIIIDOHSA-N (2S)-2-amino-3-({[2,3-bis(hexadecanoyloxy)propoxy](hydroxy)phosphoryl}oxy)propanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-HTIIIDOHSA-N 0.000 description 2
• SCVHJVCATBPIHN-SJCJKPOMSA-N (3S)-3-[[(2S)-2-[[2-(2-tert-butylanilino)-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound N([C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)COC=1C(=C(F)C=C(F)C=1F)F)C(=O)C(=O)NC1=CC=CC=C1C(C)(C)C SCVHJVCATBPIHN-SJCJKPOMSA-N 0.000 description 2
• LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 2
• IJFVSSZAOYLHEE-SSEXGKCCSA-O 1,2-dilauroyl-sn-glycero-3-phosphocholine(1+) Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-SSEXGKCCSA-O 0.000 description 2
• BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 2
• PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
• SLKDGVPOSSLUAI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(hexadecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-UHFFFAOYSA-N 0.000 description 2
• NEZDNQCXEZDCBI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(tetradecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-UHFFFAOYSA-N 0.000 description 2
• 206010065040 AIDS dementia complex Diseases 0.000 description 2
• 108010047814 Antigen-Antibody Complex Proteins 0.000 description 2
• 241000349774 Bikinia letestui Species 0.000 description 2
• 210000000988 Bone and Bones Anatomy 0.000 description 2
• 210000000481 Breast Anatomy 0.000 description 2
• 101700070842 CCR3 Proteins 0.000 description 2
• 102100005861 CCR3 Human genes 0.000 description 2
• 102100009368 CR2 Human genes 0.000 description 2
• 101700020447 CR2 Proteins 0.000 description 2
• WWXBHTZSYYGCSG-UHFFFAOYSA-N Carbarsone Chemical compound NC(=O)NC1=CC=C([As](O)(O)=O)C=C1 WWXBHTZSYYGCSG-UHFFFAOYSA-N 0.000 description 2
• 208000005623 Carcinogenesis Diseases 0.000 description 2
• 102000011727 Caspases Human genes 0.000 description 2
• 108010076667 Caspases Proteins 0.000 description 2
• 210000003855 Cell Nucleus Anatomy 0.000 description 2
• WHTVZRBIWZFKQO-UHFFFAOYSA-N Chloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
• 229960003677 Chloroquine Drugs 0.000 description 2
• 208000006154 Chronic Hepatitis C Diseases 0.000 description 2
• 108009000280 Complement Activation Proteins 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• XCLDDDHMRBWEKC-UHFFFAOYSA-N DAPI staining Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)[CH]C2=N1 XCLDDDHMRBWEKC-UHFFFAOYSA-N 0.000 description 2
• 210000003785 Decidua Anatomy 0.000 description 2
• KILNVBDSWZSGLL-KXQOOQHDSA-N Dipalmitoylphosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
• 229960004679 Doxorubicin Drugs 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 101700079540 FAS Proteins 0.000 description 2
• 229960002949 Fluorouracil Drugs 0.000 description 2
• 210000002288 Golgi Apparatus Anatomy 0.000 description 2
• 210000004013 Groin Anatomy 0.000 description 2
• JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
• 102000015140 HIV Envelope Protein gp120 Human genes 0.000 description 2
• 108010039334 HIV Envelope Protein gp120 Proteins 0.000 description 2
• 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
• 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
• 102100019442 ITGAL Human genes 0.000 description 2
• 210000000428 Immunological Synapses Anatomy 0.000 description 2
• CBVCZFGXHXORBI-PXQQMZJSSA-N Indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 2
• 206010022114 Injury Diseases 0.000 description 2
• 210000004692 Intercellular Junctions Anatomy 0.000 description 2
• 108010047761 Interferon-alpha Proteins 0.000 description 2
• 102000006992 Interferon-alpha Human genes 0.000 description 2
• 210000000936 Intestines Anatomy 0.000 description 2
• 101700014816 KLRB1 Proteins 0.000 description 2
• 102100007899 KLRB1 Human genes 0.000 description 2
• 102000007330 LDL Lipoproteins Human genes 0.000 description 2
• 108010007622 LDL Lipoproteins Proteins 0.000 description 2
• GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 229920002521 Macromolecule Polymers 0.000 description 2
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
• 210000001132 Macrophages, Alveolar Anatomy 0.000 description 2
• GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
• 108010006035 Metalloproteases Proteins 0.000 description 2
• 206010027457 Metastases to liver Diseases 0.000 description 2
• 241000186359 Mycobacterium Species 0.000 description 2
• LKQLRGMMMAHREN-YJFXYUILSA-N N-stearoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC LKQLRGMMMAHREN-YJFXYUILSA-N 0.000 description 2
• 102100007544 NCAM1 Human genes 0.000 description 2
• 101700077124 NCAM1 Proteins 0.000 description 2
• 206010025310 Other lymphomas Diseases 0.000 description 2
• 210000001672 Ovary Anatomy 0.000 description 2
• VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
• 206010057249 Phagocytosis Diseases 0.000 description 2
• 210000004011 Plasma Cells Anatomy 0.000 description 2
• 239000004698 Polyethylene (PE) Substances 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 102000007615 Pulmonary Surfactant-Associated Protein A Human genes 0.000 description 2
• 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 210000000664 Rectum Anatomy 0.000 description 2
• SHGAZHPCJJPHSC-YCNIQYBTSA-N Retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
• IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
• 229960000329 Ribavirin Drugs 0.000 description 2
• 101710006038 SCARA4 Proteins 0.000 description 2
• QWAXKHKRTORLEM-UGJKXSETSA-N Saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 2
• 229960001852 Saquinavir Drugs 0.000 description 2
• 108010078070 Scavenger Receptors Proteins 0.000 description 2
• 102000014452 Scavenger Receptors Human genes 0.000 description 2
• 229920002684 Sepharose Polymers 0.000 description 2
• 230000036703 Serum protein binding Effects 0.000 description 2
• 210000000952 Spleen Anatomy 0.000 description 2
• CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
• DKVBOUDTNWVDEP-NJCHZNEYSA-N Teicoplanin aglycon Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 2
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
• 210000001685 Thyroid Gland Anatomy 0.000 description 2
• 102000004142 Trypsin Human genes 0.000 description 2
• 108090000631 Trypsin Proteins 0.000 description 2
• HBOMLICNUCNMMY-XLPZGREQSA-N Zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
• FVJZSBGHRPJMMA-IOLBBIBUSA-N [(2R)-2,3-bis(octadecanoyloxy)propoxy][(2S)-2,3-dihydroxypropoxy]phosphinic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 description 2
• DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2R)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(Z)-octadec-9-enoyl]oxypropyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 2
• 230000035507 absorption Effects 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
• 230000003044 adaptive Effects 0.000 description 2
• 230000001070 adhesive Effects 0.000 description 2
• 239000000853 adhesive Substances 0.000 description 2
• 230000032683 aging Effects 0.000 description 2
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
• 125000000539 amino acid group Chemical group 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 230000002424 anti-apoptotic Effects 0.000 description 2
• 230000000844 anti-bacterial Effects 0.000 description 2
• 230000036436 anti-hiv Effects 0.000 description 2
• 230000000692 anti-sense Effects 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 230000003305 autocrine Effects 0.000 description 2
• 230000006399 behavior Effects 0.000 description 2
• 238000004166 bioassay Methods 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 230000036952 cancer formation Effects 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000003915 cell function Effects 0.000 description 2
• 239000002771 cell marker Substances 0.000 description 2
• 230000002490 cerebral Effects 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• 150000001841 cholesterols Chemical class 0.000 description 2
• 210000003040 circulating cell Anatomy 0.000 description 2
• 238000010549 co-Evaporation Methods 0.000 description 2
• 238000004440 column chromatography Methods 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 230000024203 complement activation Effects 0.000 description 2
• 239000012141 concentrate Substances 0.000 description 2
• 235000008504 concentrate Nutrition 0.000 description 2
• 230000000875 corresponding Effects 0.000 description 2
• 238000003381 deacetylation reaction Methods 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 230000003111 delayed Effects 0.000 description 2
• 238000000432 density-gradient centrifugation Methods 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• LHCZDUCPSRJDJT-UHFFFAOYSA-N dilauroyl phosphatidylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCC LHCZDUCPSRJDJT-UHFFFAOYSA-N 0.000 description 2
• 238000010494 dissociation reaction Methods 0.000 description 2
• 230000005593 dissociations Effects 0.000 description 2
• 230000005059 dormancy Effects 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 241001493065 dsRNA viruses Species 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 238000005538 encapsulation Methods 0.000 description 2
• 230000029578 entry into host Effects 0.000 description 2
• 210000002919 epithelial cells Anatomy 0.000 description 2
• 230000001586 eradicative Effects 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 230000001605 fetal Effects 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 238000003260 fluorescence intensity Methods 0.000 description 2
• 101700068417 fol1 Proteins 0.000 description 2
• 235000019152 folic acid Nutrition 0.000 description 2
• 239000011724 folic acid Substances 0.000 description 2
• 230000003325 follicular Effects 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 238000007710 freezing Methods 0.000 description 2
• 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 230000003899 glycosylation Effects 0.000 description 2
• 238000006206 glycosylation reaction Methods 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 238000010438 heat treatment Methods 0.000 description 2
• 231100000753 hepatic injury Toxicity 0.000 description 2
• 210000002663 immature myeloid dendritic cell Anatomy 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 230000002779 inactivation Effects 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• 229960001936 indinavir Drugs 0.000 description 2
• 230000015788 innate immune response Effects 0.000 description 2
• 102000006495 integrins Human genes 0.000 description 2
• 108010044426 integrins Proteins 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 230000002427 irreversible Effects 0.000 description 2
• 238000002372 labelling Methods 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 235000020778 linoleic acid Nutrition 0.000 description 2
• 230000004807 localization Effects 0.000 description 2
• 201000004792 malaria Diseases 0.000 description 2
• 210000004962 mammalian cells Anatomy 0.000 description 2
• 210000003798 mature myeloid dendritic cell Anatomy 0.000 description 2
• 210000003071 memory T lymphocyte Anatomy 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
• YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
• 230000001617 migratory Effects 0.000 description 2
• 230000000877 morphologic Effects 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• 210000002569 neurons Anatomy 0.000 description 2
• 239000002777 nucleoside Substances 0.000 description 2
• 150000003833 nucleoside derivatives Chemical class 0.000 description 2
• 230000014207 opsonization Effects 0.000 description 2
• 230000003571 opsonizing Effects 0.000 description 2
• 229960001756 oxaliplatin Drugs 0.000 description 2
• 210000004738 parenchymal cell Anatomy 0.000 description 2
• 102000007863 pattern recognition receptors Human genes 0.000 description 2
• 108010089193 pattern recognition receptors Proteins 0.000 description 2
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
• 230000008782 phagocytosis Effects 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 238000005191 phase separation Methods 0.000 description 2
• 235000021317 phosphate Nutrition 0.000 description 2
• 239000002953 phosphate buffered saline Substances 0.000 description 2
• 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
• OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
• 239000011574 phosphorus Substances 0.000 description 2
• 229910052698 phosphorus Inorganic materials 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
• 230000000750 progressive Effects 0.000 description 2
• DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 239000011347 resin Substances 0.000 description 2
• 229920005989 resin Polymers 0.000 description 2
• 230000003307 reticuloendothelial Effects 0.000 description 2
• 238000010839 reverse transcription Methods 0.000 description 2
• WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
• YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2R,3R,4S,5S,6R)-2-[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 2
• 238000000935 solvent evaporation Methods 0.000 description 2
• 238000011105 stabilization Methods 0.000 description 2
• 239000011550 stock solution Substances 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 230000004083 survival Effects 0.000 description 2
• 102000015609 tat Gene Products Human genes 0.000 description 2
• 108010038756 tat Gene Products Proteins 0.000 description 2
• AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 2
• 235000008170 thiamine pyrophosphate Nutrition 0.000 description 2
• 230000036962 time dependent Effects 0.000 description 2
• 239000011732 tocopherol Substances 0.000 description 2
• 229930003799 tocopherols Natural products 0.000 description 2
• 230000000699 topical Effects 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 238000010361 transduction Methods 0.000 description 2
• 230000026683 transduction Effects 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
• 229960001322 trypsin Drugs 0.000 description 2
• 239000012588 trypsin Substances 0.000 description 2
• 210000004881 tumor cells Anatomy 0.000 description 2
• 241000712461 unidentified influenza virus Species 0.000 description 2
• 239000002691 unilamellar liposome Substances 0.000 description 2
• DXXBBUOVGDAFFJ-UHFFFAOYSA-N urea;hydrobromide Chemical compound [Br-].NC(O)=[NH2+] DXXBBUOVGDAFFJ-UHFFFAOYSA-N 0.000 description 2
• 238000002255 vaccination Methods 0.000 description 2
• 229960005486 vaccines Drugs 0.000 description 2
• 238000007738 vacuum evaporation Methods 0.000 description 2
• 230000035899 viability Effects 0.000 description 2
• 239000002023 wood Substances 0.000 description 2
• DTOSIQBPPRVQHS-PDBXOOCHSA-N α-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• GUIBZZYABLMRRD-CQSZACIVSA-N (2R)-4,8-dimethoxy-9-methyl-2-propan-2-yl-2,3-dihydrofuro[2,3-b]quinolin-9-ium Chemical compound C[N+]1=C2C(OC)=CC=CC2=C(OC)C2=C1O[C@@H](C(C)C)C2 GUIBZZYABLMRRD-CQSZACIVSA-N 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
• NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
• GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
• HYFLWBNQFMXCPA-UHFFFAOYSA-N 1-ethyl-2-methylbenzene Chemical compound CCC1=CC=CC=C1C HYFLWBNQFMXCPA-UHFFFAOYSA-N 0.000 description 1
• RFVFQQWKPSOBED-PSXMRANNSA-N 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCC RFVFQQWKPSOBED-PSXMRANNSA-N 0.000 description 1
• ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-Ethoxyethanol Chemical class CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
• 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
• QPLPMPAMOJIAMN-UHFFFAOYSA-M 3-oxobutanethioate Chemical compound CC(=O)CC([O-])=S QPLPMPAMOJIAMN-UHFFFAOYSA-M 0.000 description 1
• 238000004679 31P NMR spectroscopy Methods 0.000 description 1
• LFMZGLJNFRZVBS-UHFFFAOYSA-N 5-oxopentylidyneoxidanium Chemical group O=[C-]CCCC#[O+] LFMZGLJNFRZVBS-UHFFFAOYSA-N 0.000 description 1
• 108060000228 ADRM1 Proteins 0.000 description 1
• 102100020101 AHCYL1 Human genes 0.000 description 1
• 101710024732 AHCYL1 Proteins 0.000 description 1
• 208000010310 AIDS-Related Complex Diseases 0.000 description 1
• 102100001249 ALB Human genes 0.000 description 1
• 210000001015 Abdomen Anatomy 0.000 description 1
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
• 229960000643 Adenine Drugs 0.000 description 1
• 210000002534 Adenoids Anatomy 0.000 description 1
• 210000000577 Adipose Tissue Anatomy 0.000 description 1
• 229940009444 Amphotericin Drugs 0.000 description 1
• 108010003596 Antennapedia Homeodomain Protein Proteins 0.000 description 1
• 241001409016 Arrhis Species 0.000 description 1
• 108010002913 Asialoglycoproteins Proteins 0.000 description 1
• 208000006673 Asthma Diseases 0.000 description 1
• 230000020955 B cell costimulation Effects 0.000 description 1
• 206010060945 Bacterial infection Diseases 0.000 description 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
• 241001474374 Blennius Species 0.000 description 1
• 210000000601 Blood Cells Anatomy 0.000 description 1
• 210000001772 Blood Platelets Anatomy 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 210000001124 Body Fluids Anatomy 0.000 description 1
• 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
• 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 230000005653 Brownian motion process Effects 0.000 description 1
• 229940095259 Butylated Hydroxytoluene Drugs 0.000 description 1
• 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
• 102100003755 CCNO Human genes 0.000 description 1
• 101700047412 CCNO Proteins 0.000 description 1
• 102100005826 CD19 Human genes 0.000 description 1
• 101700087100 CD19 Proteins 0.000 description 1
• 108010041397 CD4 Antigens Proteins 0.000 description 1
• 102100005833 CD68 Human genes 0.000 description 1
• 102100005832 CD69 Human genes 0.000 description 1
• 101700080416 CD69 Proteins 0.000 description 1
• 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 description 1
• 210000002791 CFU-M Anatomy 0.000 description 1
• ABLZXFCXXLZCGV-UHFFFAOYSA-L CHEBI:8154 Chemical class [O-]P([O-])=O ABLZXFCXXLZCGV-UHFFFAOYSA-L 0.000 description 1
• 101000007233 COLEC12 Proteins 0.000 description 1
• 102100014446 CYBB Human genes 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N C[N+](C)(C)CCO Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 241000220451 Canavalia Species 0.000 description 1
• 240000001452 Canavalia ensiformis Species 0.000 description 1
• 235000010520 Canavalia ensiformis Nutrition 0.000 description 1
• 229940095731 Candida albicans Drugs 0.000 description 1
• 241000222122 Candida albicans Species 0.000 description 1
• 229960004562 Carboplatin Drugs 0.000 description 1
• 102000004225 Cathepsin B Human genes 0.000 description 1
• 108090000712 Cathepsin B Proteins 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 210000002421 Cell Wall Anatomy 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 210000003679 Cervix Uteri Anatomy 0.000 description 1
• 229960004630 Chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 241000721156 Chloranthus spicatus Species 0.000 description 1
• RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 1
• 206010008635 Cholestasis Diseases 0.000 description 1
• 229960001231 Choline Drugs 0.000 description 1
• 210000003917 Chromosomes, Human Anatomy 0.000 description 1
• 102000005853 Clathrin Human genes 0.000 description 1
• 108010019874 Clathrin Proteins 0.000 description 1
• 230000035700 Clearance Rate Effects 0.000 description 1
• 208000003322 Coinfection Diseases 0.000 description 1
• 210000001072 Colon Anatomy 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 229940088900 Crixivan Drugs 0.000 description 1
• 241001559589 Cullen Species 0.000 description 1
• YPHMISFOHDHNIV-FSZOTQKASA-N Cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• 229960004397 Cyclophosphamide Drugs 0.000 description 1
• 229940119017 Cyclosporine Drugs 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• 102000009058 Death Domain Receptors Human genes 0.000 description 1
• 108010049207 Death Domain Receptors Proteins 0.000 description 1
• RGWHQCVHVJXOKC-SHYZEUOFSA-N Deoxycytidine triphosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 1
• 206010012601 Diabetes mellitus Diseases 0.000 description 1
• 229940115080 Doxil Drugs 0.000 description 1
• 108010015776 EC 1.1.3.4 Proteins 0.000 description 1
• 101700025368 ERBB2 Proteins 0.000 description 1
• 102100016662 ERBB2 Human genes 0.000 description 1
• 241001115402 Ebolavirus Species 0.000 description 1
• 210000002969 Egg Yolk Anatomy 0.000 description 1
• 241000508725 Elymus repens Species 0.000 description 1
• 210000001161 Embryo, Mammalian Anatomy 0.000 description 1
• 210000003038 Endothelium Anatomy 0.000 description 1
• 229940095399 Enema Drugs 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 241000733421 Epipactis Species 0.000 description 1
• 241001136242 Epipactis helleborine Species 0.000 description 1
• 210000000981 Epithelium Anatomy 0.000 description 1
• 229960002061 Ergocalciferol Drugs 0.000 description 1
• 235000014066 European mistletoe Nutrition 0.000 description 1
• 102100014608 FCER2 Human genes 0.000 description 1
• 101700053597 FCER2 Proteins 0.000 description 1
• 101710009074 FLT3 Proteins 0.000 description 1
• 102100004572 FLT3LG Human genes 0.000 description 1
• 101710022257 FLT3LG Proteins 0.000 description 1
• 206010048474 Fat redistribution Diseases 0.000 description 1
• 229940014144 Folate Drugs 0.000 description 1
• 229960000304 Folic Acid Drugs 0.000 description 1
• ZJAOAACCNHFJAH-UHFFFAOYSA-N Foscarnet Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 1
• 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 229940116332 GLUCOSE OXIDASE Drugs 0.000 description 1
• 241000234283 Galanthus nivalis Species 0.000 description 1
• 208000007882 Gastritis Diseases 0.000 description 1
• 229940065521 Glucocorticoid inhalants for obstructive airway disease Drugs 0.000 description 1
• 239000004366 Glucose oxidase Substances 0.000 description 1
• 108010015899 Glycopeptides Proteins 0.000 description 1
• 102000002068 Glycopeptides Human genes 0.000 description 1
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
• 102000018657 HIV Core Protein p24 Human genes 0.000 description 1
• 108010027044 HIV Core Protein p24 Proteins 0.000 description 1
• 108010083930 HIV Receptors Proteins 0.000 description 1
• 102000006481 HIV Receptors Human genes 0.000 description 1
• 102100005616 HLA-DQA2 Human genes 0.000 description 1
• 101710031486 HLA-DQA2 Proteins 0.000 description 1
• 206010019663 Hepatic failure Diseases 0.000 description 1
• 108010073141 Hepatitis C virus glycoprotein E2 Proteins 0.000 description 1
• 206010019799 Hepatitis viral Diseases 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• 241000234473 Hippeastrum Species 0.000 description 1
• 229910052689 Holmium Inorganic materials 0.000 description 1
• 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
• 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 102100004115 ICAM1 Human genes 0.000 description 1
• 101700051176 ICAM1 Proteins 0.000 description 1
• 101700046422 IFNA Proteins 0.000 description 1
• 102100008763 IFNA2 Human genes 0.000 description 1
• 101700086956 IFNG Proteins 0.000 description 1
• 102100016020 IFNG Human genes 0.000 description 1
• 101710006689 ITGAX Proteins 0.000 description 1
• 102100019437 ITGAX Human genes 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• 102000018358 Immunoglobulins Human genes 0.000 description 1
• 108060003951 Immunoglobulins Proteins 0.000 description 1
• 206010060708 Induration Diseases 0.000 description 1
• 206010061217 Infestation Diseases 0.000 description 1
• 241000283162 Inia geoffrensis Species 0.000 description 1
• 108090000467 Interferon beta Proteins 0.000 description 1
• 102000003996 Interferon beta Human genes 0.000 description 1
• 108010079944 Interferon-alpha2b Proteins 0.000 description 1
• 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
• 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
• 108010002386 Interleukin-3 Proteins 0.000 description 1
• 229940028885 Interleukin-4 Drugs 0.000 description 1
• 101700071001 KLRD1 Proteins 0.000 description 1
• 102100007895 KLRD1 Human genes 0.000 description 1
• 101710033506 Klrb1a Proteins 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 229960004488 Linolenic Acid Drugs 0.000 description 1
• 206010024606 Lipodystrophy Diseases 0.000 description 1
• 208000006132 Lipodystrophy Diseases 0.000 description 1
• 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
• 102000004895 Lipoproteins Human genes 0.000 description 1
• 108090001030 Lipoproteins Proteins 0.000 description 1
• 208000007903 Liver Failure Diseases 0.000 description 1
• 206010067125 Liver injury Diseases 0.000 description 1
• 210000004072 Lung Anatomy 0.000 description 1
• 241001124569 Lycaenidae Species 0.000 description 1
• 210000002751 Lymph Anatomy 0.000 description 1
• 208000008771 Lymphadenopathy Diseases 0.000 description 1
• 206010025280 Lymphocytosis Diseases 0.000 description 1
• 206010025650 Malignant melanoma Diseases 0.000 description 1
• 208000002720 Malnutrition Diseases 0.000 description 1
• 102000001698 Mannose-Binding Lectins Human genes 0.000 description 1
• 108010068997 Mannose-Binding Lectins Proteins 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 210000002284 Membrane Microdomains Anatomy 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 210000000713 Mesentery Anatomy 0.000 description 1
• 210000003716 Mesoderm Anatomy 0.000 description 1
• 230000036740 Metabolism Effects 0.000 description 1
• 206010027458 Metastases to lung Diseases 0.000 description 1
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
• 210000004080 Milk Anatomy 0.000 description 1
• 206010065764 Mucosal infection Diseases 0.000 description 1
• 229940090009 Myleran Drugs 0.000 description 1
• 241001626184 Myrianthus holstii Species 0.000 description 1
• OVRNDRQMDRJTHS-CBQIKETKSA-N N-ACETYL-D-GALACTOSAMINE Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
• QQGNLKJAIVSNCO-UHFFFAOYSA-N N-butylformamide Chemical compound CCCCNC=O QQGNLKJAIVSNCO-UHFFFAOYSA-N 0.000 description 1
• 108010082739 NADPH Oxidase 2 Proteins 0.000 description 1
• 210000004693 NK cell Anatomy 0.000 description 1
• 229920002957 Naked DNA Polymers 0.000 description 1
• 241001532689 Narcissus pseudonarcissus Species 0.000 description 1
• 210000002850 Nasal Mucosa Anatomy 0.000 description 1
• 102000010648 Natural Killer Cell Receptors Human genes 0.000 description 1
• 108010077854 Natural Killer Cell Receptors Proteins 0.000 description 1
• QAGYKUNXZHXKMR-HKWSIXNMSA-N Nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
• 206010053643 Neurodegenerative disease Diseases 0.000 description 1
• 108010061543 Neutralizing Antibodies Proteins 0.000 description 1
• NQDJXKOVJZTUJA-UHFFFAOYSA-N Nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 1
• 229960000689 Nevirapine Drugs 0.000 description 1
• 229920000272 Oligonucleotide Polymers 0.000 description 1
• 210000003463 Organelles Anatomy 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 229940092253 Ovalbumin Drugs 0.000 description 1
• 108010058846 Ovalbumin Proteins 0.000 description 1
• 101710043203 P23p89 Proteins 0.000 description 1
• 210000003254 Palate Anatomy 0.000 description 1
• LCCNCVORNKJIRZ-UHFFFAOYSA-N Parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
• 210000001986 Peyer's Patches Anatomy 0.000 description 1
• 210000000680 Phagosomes Anatomy 0.000 description 1
• BULVZWIRKLYCBC-UHFFFAOYSA-N Phorate Chemical compound CCOP(=S)(OCC)SCSCC BULVZWIRKLYCBC-UHFFFAOYSA-N 0.000 description 1
• 241000224017 Plasmodium berghei Species 0.000 description 1
• 229920000362 Polyethylene-block-poly(ethylene glycol) Polymers 0.000 description 1
• 102000011587 Polyproteins Human genes 0.000 description 1
• 108010076039 Polyproteins Proteins 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 108010076504 Protein Sorting Signals Proteins 0.000 description 1
• 241001579247 Psychoides Species 0.000 description 1
• 101710037934 QRSL1 Proteins 0.000 description 1
• 230000025458 RNA interference Effects 0.000 description 1
• 102100009234 RPGR Human genes 0.000 description 1
• 101700001406 RPGR Proteins 0.000 description 1
• 244000152640 Rhipsalis cassutha Species 0.000 description 1
• 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
• 102100017723 SNX1 Human genes 0.000 description 1
• 101700034230 SNX1 Proteins 0.000 description 1
• 229940100996 SODIUM BISULFATE Drugs 0.000 description 1
• 108090000184 Selectins Proteins 0.000 description 1
• 102000003800 Selectins Human genes 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• WBHQBSYUUJJSRZ-UHFFFAOYSA-M Sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
• 229940043517 Specific immunoglobulins Drugs 0.000 description 1
• WWUZIQQURGPMPG-KRWOKUGFSA-N Sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
• 229910000831 Steel Inorganic materials 0.000 description 1
• 210000002536 Stromal Cells Anatomy 0.000 description 1
• 229940037128 Systemic Glucocorticoids Drugs 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• 108091008153 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 210000000662 T-Lymphocyte Subsets Anatomy 0.000 description 1
• 210000003283 T-Lymphocytes, Helper-Inducer Anatomy 0.000 description 1
• 231100000288 TD50 Toxicity 0.000 description 1
• 108010006785 Taq Polymerase Proteins 0.000 description 1
• SGOIRFVFHAKUTI-ZCFIWIBFSA-N Tenofovir Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 description 1
• 229960004556 Tenofovir Drugs 0.000 description 1
• UMGDCJDMYOKAJW-UHFFFAOYSA-N Thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
• 210000001541 Thymus Gland Anatomy 0.000 description 1
• 230000036335 Tissue distribution Effects 0.000 description 1
• 229960001295 Tocopherol Drugs 0.000 description 1
• 102000004338 Transferrin Human genes 0.000 description 1
• 108090000901 Transferrin Proteins 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• 240000004013 Trichosanthes cucumerina Species 0.000 description 1
• 235000008322 Trichosanthes cucumerina Nutrition 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 102000009270 Tumour necrosis factor alpha Human genes 0.000 description 1
• 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 1
• LOIYMIARKYCTBW-OWOJBTEDSA-N Urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
• 229940029983 VITAMINS Drugs 0.000 description 1
• 229940023080 Viracept Drugs 0.000 description 1
• 108020005202 Viral DNA Proteins 0.000 description 1
• 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
• 102000004640 Viral Envelope Proteins Human genes 0.000 description 1
• 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
• 229960002555 Zidovudine Drugs 0.000 description 1
• RYCNUMLMNKHWPZ-SNVBAGLBSA-N [(2R)-3-acetyloxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
• QNEPTKZEXBPDLF-JDTILAPWSA-N [(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] carbonochloridate Chemical compound C1C=C2C[C@@H](OC(Cl)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QNEPTKZEXBPDLF-JDTILAPWSA-N 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 230000001154 acute Effects 0.000 description 1
• 230000033289 adaptive immune response Effects 0.000 description 1
• 230000004721 adaptive immunity Effects 0.000 description 1
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
• 102000029988 adhesion receptors Human genes 0.000 description 1
• 108010013985 adhesion receptors Proteins 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 230000000240 adjuvant Effects 0.000 description 1
• 231100000494 adverse effect Toxicity 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 230000004523 agglutinating Effects 0.000 description 1
• 229940050528 albumin Drugs 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
• 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 235000001014 amino acid Nutrition 0.000 description 1
• 150000003862 amino acid derivatives Chemical class 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 230000036592 analgesia Effects 0.000 description 1
• 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
• 230000006909 anti-apoptosis Effects 0.000 description 1
• 230000003217 anti-cancerogenic Effects 0.000 description 1
• 230000003466 anti-cipated Effects 0.000 description 1
• 230000003510 anti-fibrotic Effects 0.000 description 1
• 230000000843 anti-fungal Effects 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 229940121363 anti-inflammatory agents Drugs 0.000 description 1
• 230000000845 anti-microbial Effects 0.000 description 1
• 230000003460 anti-nuclear Effects 0.000 description 1
• 230000000259 anti-tumor Effects 0.000 description 1
• 230000002155 anti-virotic Effects 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 239000000158 apoptosis inhibitor Substances 0.000 description 1
• 239000012300 argon atmosphere Substances 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 1
• 244000052616 bacterial pathogens Species 0.000 description 1
• 239000002585 base Substances 0.000 description 1
• 230000003542 behavioural Effects 0.000 description 1
• 238000006065 biodegradation reaction Methods 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• 230000000903 blocking Effects 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• 238000005537 brownian motion Methods 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 235000012970 cakes Nutrition 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-N carbamate Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 201000009030 carcinoma Diseases 0.000 description 1
• 238000005266 casting Methods 0.000 description 1
• 230000001364 causal effect Effects 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 229920002083 cellular DNA Polymers 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 230000005591 charge neutralization Effects 0.000 description 1
• 231100000359 cholestasis Toxicity 0.000 description 1
• 108010011793 cholesterol-binding protein Proteins 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 201000009446 chronic granulomatous disease Diseases 0.000 description 1
• 231100000160 chronic toxicity Toxicity 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• 238000007697 cis-trans-isomerization reaction Methods 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 238000005352 clarification Methods 0.000 description 1
• 230000001149 cognitive Effects 0.000 description 1
• 201000010897 colon adenocarcinoma Diseases 0.000 description 1
• 230000023298 conjugation with cellular fusion Effects 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 230000036461 convulsion Effects 0.000 description 1
• 235000014987 copper Nutrition 0.000 description 1
• 230000004940 costimulation Effects 0.000 description 1
• 238000005138 cryopreservation Methods 0.000 description 1
• 230000002338 cryopreservative Effects 0.000 description 1
• 230000001082 cryoprotectant Effects 0.000 description 1
• 239000002577 cryoprotective agent Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000005712 crystallization Effects 0.000 description 1
• 238000002447 crystallographic data Methods 0.000 description 1
• 108060002021 cyanovirin N Proteins 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 239000000409 cytokine receptor agonist Substances 0.000 description 1
• 239000000430 cytokine receptor antagonist Substances 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 230000000120 cytopathologic Effects 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• SUYVUBYJARFZHO-RRKCRQDMSA-J dATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-J 0.000 description 1
• NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
• 235000013365 dairy product Nutrition 0.000 description 1
• 230000003247 decreasing Effects 0.000 description 1
• 230000005860 defense response to virus Effects 0.000 description 1
• 230000003412 degenerative Effects 0.000 description 1
• 230000005595 deprotonation Effects 0.000 description 1
• 238000010537 deprotonation reaction Methods 0.000 description 1
• 230000003831 deregulation Effects 0.000 description 1
• 230000001687 destabilization Effects 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 230000001627 detrimental Effects 0.000 description 1
• XLLNINGEDIOQGQ-UHFFFAOYSA-M diacetyl phosphate Chemical compound CC(=O)OP([O-])(=O)OC(C)=O XLLNINGEDIOQGQ-UHFFFAOYSA-M 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
• 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• 231100000676 disease causative agent Toxicity 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 150000002019 disulfides Chemical group 0.000 description 1
• 239000012154 double-distilled water Substances 0.000 description 1
• 230000035622 drinking Effects 0.000 description 1
• 235000021271 drinking Nutrition 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 238000002296 dynamic light scattering Methods 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 210000003162 effector T lymphocyte Anatomy 0.000 description 1
• 235000013345 egg yolk Nutrition 0.000 description 1
• 235000013601 eggs Nutrition 0.000 description 1
• 230000000534 elicitor Effects 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 239000002158 endotoxin Substances 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 230000002255 enzymatic Effects 0.000 description 1
• 210000003426 epidermal Langerhans cell Anatomy 0.000 description 1
• 235000004626 essential fatty acids Nutrition 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• 239000002038 ethyl acetate fraction Substances 0.000 description 1
• PPCXFTKZPBHXIW-UHFFFAOYSA-N ethyl ethanesulfonate Chemical compound CCOS(=O)(=O)CC PPCXFTKZPBHXIW-UHFFFAOYSA-N 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000001747 exhibiting Effects 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 101700051312 fadI Proteins 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 230000004634 feeding behavior Effects 0.000 description 1
• 210000002557 fixed macrophage Anatomy 0.000 description 1
• 238000003818 flash chromatography Methods 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 210000001579 follicular dendritic cell Anatomy 0.000 description 1
• 229960005102 foscarnet Drugs 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 150000008267 fucoses Chemical class 0.000 description 1
• QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 1
• 230000002068 genetic Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 150000002298 globosides Chemical class 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 235000019420 glucose oxidase Nutrition 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 125000003147 glycosyl group Chemical group 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 230000003179 granulation Effects 0.000 description 1
• 238000005469 granulation Methods 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 230000002324 hematogenic Effects 0.000 description 1
• 231100000234 hepatic damage Toxicity 0.000 description 1
• 230000000423 heterosexual Effects 0.000 description 1
• 239000004030 hiv protease inhibitor Substances 0.000 description 1
• 239000000710 homodimer Substances 0.000 description 1
• 102000036075 human COLEC12 protein Human genes 0.000 description 1
• 244000052637 human pathogens Species 0.000 description 1
• 230000028996 humoral immune response Effects 0.000 description 1
• 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
• 238000005984 hydrogenation reaction Methods 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 229940050526 hydroxyethylstarch Drugs 0.000 description 1
• 230000003463 hyperproliferative Effects 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 239000012216 imaging agent Substances 0.000 description 1
• 150000002460 imidazoles Chemical class 0.000 description 1
• 230000003100 immobilizing Effects 0.000 description 1
• 230000002519 immonomodulatory Effects 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 230000003344 immunostimulant Effects 0.000 description 1
• 239000003022 immunostimulating agent Substances 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 230000003116 impacting Effects 0.000 description 1
• 230000001976 improved Effects 0.000 description 1
• 238000000126 in silico method Methods 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 230000000415 inactivating Effects 0.000 description 1
• 229910052738 indium Inorganic materials 0.000 description 1
• 230000001524 infective Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 239000003999 initiator Substances 0.000 description 1
• 230000000977 initiatory Effects 0.000 description 1
• 230000011488 interferon-alpha production Effects 0.000 description 1
• 239000011229 interlayer Substances 0.000 description 1
• 230000004073 interleukin-2 production Effects 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000010212 intracellular staining Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000007915 intraurethral administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
• 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
• 238000011031 large scale production Methods 0.000 description 1
• 235000020129 lassi Nutrition 0.000 description 1
• 230000003902 lesions Effects 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal Effects 0.000 description 1
• 230000004301 light adaptation Effects 0.000 description 1
• 108010049645 liposome-encapsulated hemoglobin Proteins 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 201000004044 liver cirrhosis Diseases 0.000 description 1
• 231100000835 liver failure Toxicity 0.000 description 1
• 230000007787 long-term memory Effects 0.000 description 1
• 229940113983 lopinavir / Ritonavir Drugs 0.000 description 1
• 238000000464 low-speed centrifugation Methods 0.000 description 1
• 230000001926 lymphatic Effects 0.000 description 1
• 230000002934 lysing Effects 0.000 description 1
• 238000007403 mPCR Methods 0.000 description 1
• 108091005488 macrophage receptors Proteins 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
• 235000019341 magnesium sulphate Nutrition 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 230000031852 maintenance of location in cell Effects 0.000 description 1
• 102000027675 major histocompatibility complex family Human genes 0.000 description 1
• 108091007937 major histocompatibility complex family Proteins 0.000 description 1
• PEEHTFAAVSWFBL-UHFFFAOYSA-N maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
• 230000003211 malignant Effects 0.000 description 1
• 230000001071 malnutrition Effects 0.000 description 1
• 235000000824 malnutrition Nutrition 0.000 description 1
• 108020003928 mannose binding proteins Proteins 0.000 description 1
• 102000021159 mannose binding proteins Human genes 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 210000004779 membrane envelope Anatomy 0.000 description 1
• 102000006240 membrane receptors Human genes 0.000 description 1
• 108020004084 membrane receptors Proteins 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 230000035786 metabolism Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• FRSRGACXHCLBTC-UHFFFAOYSA-N methyl N-(3,5-dichlorophenyl)carbamate Chemical compound COC(=O)NC1=CC(Cl)=CC(Cl)=C1 FRSRGACXHCLBTC-UHFFFAOYSA-N 0.000 description 1
• HOVAGTYPODGVJG-VEIUFWFVSA-N methyl α-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 1
• 239000011325 microbead Substances 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 238000000329 molecular dynamics simulation Methods 0.000 description 1
• 210000000947 motile cell Anatomy 0.000 description 1
• 230000004899 motility Effects 0.000 description 1
• 201000009457 movement disease Diseases 0.000 description 1
• 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000002077 nanosphere Substances 0.000 description 1
• 230000004719 natural immunity Effects 0.000 description 1
• 229940042880 natural phospholipids Drugs 0.000 description 1
• 229960000884 nelfinavir Drugs 0.000 description 1
• 230000001613 neoplastic Effects 0.000 description 1
• 230000001537 neural Effects 0.000 description 1
• 230000004766 neurogenesis Effects 0.000 description 1
• 230000002981 neuropathic Effects 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 230000003472 neutralizing Effects 0.000 description 1
• 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
• 239000012038 nucleophile Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 230000000474 nursing Effects 0.000 description 1
• 230000000414 obstructive Effects 0.000 description 1
• 210000000287 oocyte Anatomy 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 239000012074 organic phase Substances 0.000 description 1
• 230000003204 osmotic Effects 0.000 description 1
• 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
• 201000008125 pain agnosia Diseases 0.000 description 1
• 230000003071 parasitic Effects 0.000 description 1
• 230000003950 pathogenic mechanism Effects 0.000 description 1
• OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
• 210000004786 perivascular cells Anatomy 0.000 description 1
• 230000000275 pharmacokinetic Effects 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• 125000001095 phosphatidyl group Chemical group 0.000 description 1
• 150000008105 phosphatidylcholines Chemical class 0.000 description 1
• 150000003905 phosphatidylinositols Chemical class 0.000 description 1
• 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 1
• 150000003009 phosphonic acids Chemical class 0.000 description 1
• XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 1
• 230000000886 photobiology Effects 0.000 description 1
• 230000001885 phytohemagglutinin Effects 0.000 description 1
• 230000001817 pituitary Effects 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 239000001184 potassium carbonate Substances 0.000 description 1
• 229910000027 potassium carbonate Inorganic materials 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 230000002062 proliferating Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
• 230000001915 proofreading Effects 0.000 description 1
• 230000000644 propagated Effects 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000002633 protecting Effects 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 230000005588 protonation Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 238000003908 quality control method Methods 0.000 description 1
• 108010043277 recombinant soluble CD4 Proteins 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 230000001172 regenerating Effects 0.000 description 1
• 229960003471 retinol Drugs 0.000 description 1
• 235000020944 retinol Nutrition 0.000 description 1
• 239000011607 retinol Substances 0.000 description 1
• 230000001177 retroviral Effects 0.000 description 1
• 230000002987 rna-interference Effects 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 238000010187 selection method Methods 0.000 description 1
• SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• 239000010454 slate Substances 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
• QLNOOKSBAYIHQI-SKZICHJRSA-M sodium;2,3-dihydroxypropyl [(2R)-2,3-di(tetradecanoyloxy)propyl] phosphate Chemical compound [Na+].CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC QLNOOKSBAYIHQI-SKZICHJRSA-M 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 108010048090 soybean lectin Proteins 0.000 description 1
• 239000008347 soybean phospholipid Substances 0.000 description 1
• 150000003408 sphingolipids Chemical class 0.000 description 1
• 210000004215 spores Anatomy 0.000 description 1
• 230000003068 static Effects 0.000 description 1
• REYJJPSVUYRZGE-UHFFFAOYSA-N stearylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
• 239000010959 steel Substances 0.000 description 1
• 238000009168 stem cell therapy Methods 0.000 description 1
• 238000009580 stem-cell therapy Methods 0.000 description 1
• 230000003335 steric effect Effects 0.000 description 1
• 230000002739 subcortical Effects 0.000 description 1
• 150000003871 sulfonates Chemical class 0.000 description 1
• 230000002459 sustained Effects 0.000 description 1
• 230000005700 syncytium formation by plasma membrane fusion Effects 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 101700042113 tap Proteins 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• ZFQWJXFJJZUVPI-UHFFFAOYSA-N tert-butyl N-(4-aminobutyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCN ZFQWJXFJJZUVPI-UHFFFAOYSA-N 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• XVTUQDWPJJBEHJ-KZCWQMDCSA-N tetrastearoyl cardiolipin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)CO[P@@](O)(=O)OCC(O)CO[P@](O)(=O)OC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC XVTUQDWPJJBEHJ-KZCWQMDCSA-N 0.000 description 1
• 238000010257 thawing Methods 0.000 description 1
• 125000003396 thiol group Chemical class [H]S* 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 230000036964 tight binding Effects 0.000 description 1
• 235000010384 tocopherol Nutrition 0.000 description 1
• 125000002640 tocopherol group Chemical group 0.000 description 1
• 235000019149 tocopherols Nutrition 0.000 description 1
• 231100000583 toxicological profile Toxicity 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 239000012581 transferrin Substances 0.000 description 1
• 230000001131 transforming Effects 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 230000014599 transmission of virus Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 230000001960 triggered Effects 0.000 description 1
• 230000010415 tropism Effects 0.000 description 1
• 244000045561 useful plants Species 0.000 description 1
• 230000029812 viral genome replication Effects 0.000 description 1
• 201000001862 viral hepatitis Diseases 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
• 235000001892 vitamin D2 Nutrition 0.000 description 1
• 239000011653 vitamin D2 Substances 0.000 description 1
• 229930003231 vitamins Natural products 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1
• GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1